Immuron (IMRN) Income from Continuing Operations (2016 - 2024)
Immuron (IMRN) posted quarterly Income from Continuing Operations of 1.660259165668942e+18 for Q4 2024, up 80082653894883.1% year-over-year from N/an in Q1 2024, and up 80082653894883.1% quarter-over-quarter from 2073182.0 in Q4 2023.
Immuron (IMRN) Income from Continuing Operations (2016 - 2024) Analysis & Trends
Immuron's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 1.660259165668942e+18 for Q4 2024.
- In Q4 2024, Income from Continuing Operations rose 80082653894883.1% year-over-year to 1.660259165668942e+18; the TTM figure through Dec 2024 stood at 1.6602591656652777e+18 (up 45144772871889.63% YoY), while the FY2025 annual figure was 3381514.2, up 25.67% from the prior year.
- Income from Continuing Operations for Q4 2024 stood at 1.660259165668942e+18, up from 2073182.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1.660259165668942e+18 in Q4 2024, with the low at 2073182.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 204929.12 (2022), against an average of 2.7670986094420118e+17.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 2558.11% in 2022, then jumped 80082653894883.1% in 2024.
- Immuron's Income from Continuing Operations stood at 57387.72 in 2020, then surged by 76.89% to 13260.17 in 2021, then plunged by 2558.11% to 352470.52 in 2022, then tumbled by 488.19% to 2073182.0 in 2023, then surged by 80082653894883.1% to 1.660259165668942e+18 in 2024.
- Business Quant data shows IMRN's Income from Continuing Operations at 1.660259165668942e+18 in Q4 2024, 2073182.0 in Q4 2023, and 1238720.54 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,660,259,165.67 Bn |
| Dec 31, 2023 | -2.07 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -352,470.52 |
| Dec 31, 2021 | -13,260.17 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | -1.45 Mn |
| Dec 31, 2016 | -2.60 Mn |
| Jun 30, 2016 | -3.28 Mn |